Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

2026.01.31
HER2-positive breast cancer was once associated with aggressive behavior and poor prognosis. However, with the rapid advancement of targeted therapies—particularly antibody–drug conjugates (ADCs)—this subtype has evolved into a highly treatable and potentially curable disease. In 2025, landmark studies across neoadjuvant, adjuvant, and metastatic settings have reshaped treatment paradigms toward greater precision and individualization. During the 2025 Yixian Breast Cancer Conference and CSCO BC South Forum, Oncology Frontier interviewed Professor Chang Gong from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, who summarized the most impactful annual advances in HER2-positive breast cancer treatment.
2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes

2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes

2026.01.31
The 2025 Yixian Breast Cancer Conference, held alongside the 2025 CSCO Breast Cancer Southern Forum, the Second Chinese Young Breast Cancer Consensus Conference, and the Fourth Yixian Breast Cancer Nursing Conference, took place in Guangzhou on December 26–27, 2025. The meeting focused on standardization of breast cancer care, emerging therapeutic strategies, and precision management in young breast cancer patients, highlighting the latest scientific advances and future clinical directions.
Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines

Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines

2026.01.31
As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under national insurance coverage, the past year has witnessed profound shifts in breast cancer management.
Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

2026.01.31
Breast cancer has recently surpassed lung cancer as the most commonly diagnosed cancer among women worldwide. The status of regional lymph node involvement remains a key prognostic factor, directly influencing disease staging, treatment planning, and survival outcomes. While axillary lymph node dissection (ALND) has long been the standard for staging, it carries substantial morbidity. As modern breast surgery moves toward precision and minimally invasive approaches, sentinel lymph node biopsy (SLNB) has replaced ALND as the preferred axillary staging strategy, significantly reducing surgical trauma and complications.
2026 CASH | Science Knows No Borders, Cooperation Shapes the Future: A Dialogue with International Forum Chair Professor Toshio Suda

2026 CASH | Science Knows No Borders, Cooperation Shapes the Future: A Dialogue with International Forum Chair Professor Toshio Suda

2026.01.30
As a new year begins, global leaders in hematology gathered in Tianjin from January 9–11, 2026, for the 6th China Hematology Discipline Development Conference (CASH). This year’s congress introduced its first-ever International Forum, establishing a new bridge for in-depth dialogue between Chinese and global hematology communities. As one of the Forum Chairs, Professor Toshio Suda of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, brings both international perspective and profound academic influence to the field. Oncology Frontier – Hematology Frontier invited Professor Suda to share the vision behind launching the International Forum, reflect on its key highlights and collaborative achievements, and offer strategic insights on strengthening China’s integration into the global hematology landscape, further advancing international scientific exchange.
Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special

Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special

2026.01.30
The 2025 American Society of Hematology (ASH) Annual Meeting recently concluded in Orlando, USA, showcasing major breakthroughs in lymphoma research and offering new directions for optimizing clinical care. To translate cutting-edge science into clinical insight, Oncology Frontier – Hematology Frontier partners with Professor Qingqing Cai of Sun Yat-sen University Cancer Center to present the “Lymphoma Insights – ASH Special” series, delivering authoritative interpretation of landmark lymphoma studies with practical clinical relevance.
CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

2026.01.30
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held in Tianjin. The meeting brought together leading international and national experts in hematology, focusing on frontier scientific advances and national health priorities, fostering deep academic exchange and shaping future directions of the discipline.
CASH 2026 | Professor Jian Li: Peking Union Medical College Hospital’s Experience in the Diagnosis and Treatment of AL Amyloidosis

CASH 2026 | Professor Jian Li: Peking Union Medical College Hospital’s Experience in the Diagnosis and Treatment of AL Amyloidosis

2026.01.30
As the new year begins, leading experts gathered in Tianjin. From  January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held, bringing together top hematology specialists from China and abroad. The conference focused on cutting-edge scientific progress and national health priorities, fostering in-depth discussions on the future of hematology.
CASH 2026 | Academician Tao Cheng: From “Hematologic Ecology” to a “Greater Hematology” Vision—Charting a New Blueprint for Hematology in China’s 15th Five-Year Plan

CASH 2026 | Academician Tao Cheng: From “Hematologic Ecology” to a “Greater Hematology” Vision—Charting a New Blueprint for Hematology in China’s 15th Five-Year Plan

2026.01.30
From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin. Coinciding with the launch of China’s 15th Five-Year Plan, the conference centered on the theme “Tianjin: Renewing Momentum, Intelligence Leading the Future.” With a forward-looking perspective, the meeting focused on the systemic evolution and ecological integration of hematology, exploring high-quality discipline development pathways and innovative models within the broader “Healthy China” framework.